Company Overview

Decision Diagnostics Corp. (OTC: DECN) was a healthcare and diagnostics company focused on low-cost medical testing products, primarily in the diabetes monitoring and point-of-care diagnostics markets. The company operated through subsidiaries including PharmaTech Solutions, Inc. and marketed blood glucose testing systems, disposable glucose test strips, and related diabetic supplies intended for retail and consumer healthcare channels. Public disclosures and OTC market materials indicate that the company sought to compete primarily on pricing and compatibility with existing glucose meter platforms.

The company evolved from a small diagnostics and intellectual property-focused business into a developer and marketer of diabetic testing products targeting both U.S. and international markets. During the COVID-19 pandemic, Decision Diagnostics publicly promoted development efforts related to rapid coronavirus testing technologies, although several claims made during that period became the subject of regulatory scrutiny. Publicly available information indicates that trading in the company’s securities was suspended by the U.S. Securities and Exchange Commission in 2020, and subsequent public reporting activity became limited. Data regarding the company’s current operating status is inconclusive based on available public sources.

Business Operations

Decision Diagnostics generated revenue primarily through the sale and distribution of diabetic testing supplies, including glucose meters and compatible testing strips. Its operations centered around PharmaTech Solutions, Inc., which developed private-label and direct-to-consumer diabetic products positioned as lower-cost alternatives to branded offerings from larger medical device manufacturers. The company also pursued licensing, intellectual property commercialization, and diagnostic technology development initiatives.

The company’s activities were concentrated primarily in the United States, though management disclosures referenced international distribution ambitions and relationships with overseas manufacturing and supply-chain partners. Public filings and investor communications referenced development work tied to rapid diagnostic testing technologies, including COVID-19 screening concepts during 2020. However, multiple public regulatory actions and enforcement-related disclosures created uncertainty around commercialization outcomes and operational continuity. Data concerning current active subsidiaries, partnerships, and revenue-producing operations remains inconclusive based on available public sources.

Strategic Position & Investments

Decision Diagnostics positioned itself as a value-oriented diagnostics company seeking to address affordability gaps in diabetic testing products. Its strategy focused on developing compatible glucose monitoring systems that could compete against larger healthcare companies on price while leveraging retail distribution and direct sales opportunities. The company also emphasized intellectual property claims and diagnostic innovation as part of its growth narrative.

A significant strategic focus during 2020 involved the promotion of COVID-19 testing technologies and related commercialization plans. Public disclosures referenced investments in rapid testing development and manufacturing readiness through PharmaTech Solutions, Inc. Regulatory scrutiny from the SEC and other authorities materially affected the company’s public-market standing and visibility thereafter. Information regarding completed acquisitions, active investment programs, or currently operating portfolio entities cannot be conclusively verified from recent public disclosures.

Geographic Footprint

Decision Diagnostics was headquartered in the United States, with operations and commercial focus primarily tied to the domestic healthcare diagnostics market. Public materials indicated efforts to establish broader market access through manufacturing relationships and distribution channels connected to international suppliers, particularly in components and medical testing production.

The company’s commercial ambitions extended beyond North America through references to international licensing, sourcing, and distribution discussions. However, verifiable evidence of substantial long-term operational infrastructure outside the United States is limited in publicly available records. Data regarding active international facilities, regional offices, or current cross-border operational influence is inconclusive based on available public sources.

Leadership & Governance

Decision Diagnostics was closely associated with founder-led management during much of its public operating history. Leadership strategy emphasized low-cost diagnostic accessibility, intellectual property development, and expansion into rapid testing technologies. Public disclosures and regulatory filings reflected a highly centralized executive structure, particularly during the company’s later years as a publicly traded issuer.

Key executives publicly associated with the company included:

• Keith Berman – Chief Executive Officer and Chairman
• Martha S. Berman – Corporate Secretary and executive leadership roles reported in company filings

Public reporting regarding additional active executive leadership, independent governance structure, or current board composition is limited. Data concerning the company’s present governance status and management continuity is inconclusive based on available public sources.